Penn Center for Innovation

PCI is proud to work with industry partners to form Alliances— multi-year Research & Development partnerships between Penn faculty and Industry stakeholders with a goal of facilitating commercialization of ideas into products or servicesThese relationships allow Penn technologies and inventors to develop further and reach broader audiences.


Current Penn Alliances

  • Biogen – gene therapy and gene editing
  • Celgene – oncology and epigenetics
  • Incyte – discovery-stage oncology programs
  • Janssen – gene therapy for flu and Alzheimer’s
  • Novartis – CAR-T for oncology
  • Parker – Immuno-oncology
  • Tmunity – T-cell therapies and related technology
  • REGENXBIO – gene therapy for wet-AMD MPSI, MPSII, HhFH and several other earlier stage programs
  • Dimension – several liver gene therapy programs
  • Audentes – gene therapy for Crigler-Najjar

alliance logos


Alliance Statistics

In FY2017, Alliances played an important role in Penn’s commercialization activities, including disclosures, Patents Filed, and Patents Issued.

FY2017  Alliances Activity Dashboard
Alliances Metric All PCI % Alliances
113 Disclosures 370 31%
413 Patents Filed 869 48%
47 US Patents Issued 111 42%


Alliances in the News

February 23, 2017 – University of Pennsylvania Announces Cancer Research Alliance with Incyte

August 10, 2017 – Cancer’s Newest Miracle Cure

August 30, 2017 – Penn’s ‘Living Drug’ For Tough Childhood Leukemia Gains Historic Approval

September 2017 – U Penn ramps up industry sponsorships as percent of funding jumps from 6% to 15%

November 6, 2017 – With 2-pronged filing, Novartis’ CAR-T med Kymriah aims to jump into Europe with both feet